Adeno-Associated Viral Gene Therapy for Inherited Retinal Disease
Inherited retinal diseases (IRDs) are a group of rare, heterogenous eye disorders caused by gene mutations that result in degeneration of the retina. There are currently limited treatment options for IRDs; however, retinal gene therapy holds great promise for the treatment of different forms of inherited blindness. One such IRD for which gene therapy has shown positive initial results is choroideremia, a rare, X-linked degenerative disorder of the retina and choroid. Mutation of the CHM gene leads to an absence of functional Rab escort protein 1 (REP1), which causes retinal pigment epithelium cell death and photoreceptor degeneration. The condition presents in childhood as night blindness, followed by progressive constriction of visual fields, generally leading to vision loss in early adulthood and total blindness thereafter. A recently developed adeno-associated virus-2 (AAV2) vector construct encoding REP1 (AAV2-REP1) has been shown to deliver a functional version of the CHM gene into the retinal pigment epithelium and photoreceptor cells. Phase 1 and 2 studies of AAV2-REP1 in patients with choroideremia have produced encouraging results, suggesting that it is possible not only to slow or stop the decline in vision following treatment with AAV2-REP1, but also to improve visual acuity in some patients.
KeywordsAAV2-REP1 choroideremia gene therapy retina
Autosomal dominant retinitis pigmentosa
Autosomal recessive retinitis pigmentosa
Best-corrected visual acuity
Balanced salt solution
CMV enhancer-CBA promoter-rabbit β-globin splice acceptor site
Clustered Regularly Interspersed Short Palindromic Repeats
Early Treatment Diabetic Retinopathy Study
Wild-type human CHM cDNA
Inherited retinal diseases
Multiplicity of infection
Optical coherence tomography
Open reading frame 15
Rab escort protein 1
Rab escort protein 2
Retinal pigment epithelium
Retinal pigment epithelial 65-kDa protein
Retinitis pigmentosa guanosine triphosphate hydrolase regulator
Woodchuck hepatitis virus posttranscriptional regulatory element
X-linked retinitis pigmentosa
Acknowledgments and Disclosures
Figure 1 images courtesy of DGB. Editorial support was provided by Rebecca Franklin of Fishawack Communications Ltd. and funded by Nightstar Therapeutics. Tuyen Ong is an employee and equity holder of Nightstar Therapeutics. Mark E. Pennesi is a consultant for AGTC, Astellas, Biogen, Editas, FFB, Gensight, Horama, Ionis, Nacuity, Nightstar Therapeutics, Ophthotech, ProQR Therapeutics, RegenexBio, Sanofi, and Spark Therapeutics, and has received clinical trial support from AGTC and Nightstar Therapeutics. His institution has received support through grant P30 EY010572 from the National Institutes of Health (Bethesda, MD), and by unrestricted departmental funding from Research to Prevent Blindness (New York, NY). David G. Birch is a consultant for Acucela, AGTC, Editas, Genentech, Ionis, Nacuity, and Nightstar Therapeutics, and has received clinical trial support from AGTC, Nightstar, Ionis, and 4D Therapeutics, and grant support through EY09076 from the National Institutes of Health (Bethesda, MD, USA) and from the Foundation Fighting Blindness. Byron L. Lam declares he has no conflict of interest. Stephen H. Tsang declares he has no conflict of interest.
- 8.US Food and Drug Administration. FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss. 2017. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm589467.htm. Accessed 18 May 2018.
- 9.Spark Therapeutics Inc. LUXTURNA™ US Prescribing Information. Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM589541.pdf. Accessed 20 April 2018.
- 10.Bennett J, Wellman J, Marshall KA, McCague S, Ashtari M, DiStefano-Pappas J, et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet. 2016;388(10045):661–72.PubMedPubMedCentralCrossRefGoogle Scholar
- 11.Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390(10097):849–60.PubMedPubMedCentralCrossRefGoogle Scholar
- 13.Sengillo JD, Justus S, Cabral T, Tsang SH. Correction of monogenic and common retinal disorders with gene therapy. Genes (Basel). 2017;8(2). https://doi.org/10.3390/genes8020053.
- 19.Binley K, Widdowson P, Loader J, Kelleher M, Iqball S, Ferrige G, et al. Transduction of photoreceptors with equine infectious anemia virus lentiviral vectors: safety and biodistribution of StarGen for Stargardt disease. Invest Ophthalmol Vis Sci. 2013;54(6):4061–71.PubMedPubMedCentralCrossRefGoogle Scholar
- 24.McClements ME, Barnard AR, Singh MS, Charbel Issa P, Jiang Z, Radu RA, et al. An AAV dual vector strategy ameliorates the Stargardt phenotype in adult Abca4−/− mice. Hum Gene Ther. 2018. https://doi.org/10.1089/hum.2018.156 [Epub ahead of print].
- 27.Clinical Trials. Gene therapy for X-linked retinitis pigmentosa (XLRP) retinitis pigmentosa GTPase regulator (RPGR). Available from: https://clinicaltrials.gov/ct2/show/NCT03252847?term=NCT03252847&rank=1. Accessed 7 September 2018.
- 28.Clinical Trials. Safety and efficacy of rAAV2tYF-GRK1-RPGR in subjects with X-linked retinitis pigmentosa caused by RPGR-ORF15 mutations. Available from: https://clinicaltrials.gov/ct2/show/NCT03316560?term=NCT03316560&rank=1. Accessed 6 September 2018.
- 29.Clinical Trials. A clinical trial of retinal gene therapy for X-linked retinitis pigmentosa (XIRIUS). Available from: https://clinicaltrials.gov/ct2/show/NCT03116113?term=XIRIUS&rank=1. Accessed 13 September 2018.
- 30.Clinical Trials. Safety and efficacy study in patients with retinitis pigmentosa due to mutations in PDE6B gene. Available from: https://clinicaltrials.gov/ct2/show/NCT03328130. Accessed 21 September 2018.
- 31.Clinical Trials. Efficacy study of GS010 for the treatment of vision loss up to 6 months from onset in LHON due to the ND4 mutation (RESCUE). Available from: https://clinicaltrials.gov/ct2/show/NCT02652767?term=NCT02652767&rank=1. Accessed 13 September 2018.
- 33.Clinical Trials. A follow-up study to evaluate the safety of RetinoStat® in patients with age-related macular degeneration. Available from: https://clinicaltrials.gov/ct2/show/NCT01678872. Accessed 21 November 2018.
- 34.Clinical Trials. A study to determine the long-term safety, tolerability and biological activity of UshStat® in patients with Usher syndrome type 1B. Available from: https://clinicaltrials.gov/ct2/show/NCT02065011. Accessed 21 November 2018.
- 35.Clinical Trials. Study of UshStat in patients with retinitis pigmentosa associated with Usher syndrome type 1B. Available from: https://clinicaltrials.gov/ct2/show/NCT01505062. Accessed 21 November 2018.
- 40.Daiger SP, Rossiter BJF, Greenberg J, Christoffels A, Hide W. Data services and software for identifying genes and mutations causing retinal degeneration. Invest Ophthalmol Vis Sci. 1998;39:S295.Google Scholar
- 50.Fischer MD, McClements ME, Martinez-Fernandez De la Camara C, Bellingrath JS, Dauletbekov D, Ramsden SC, et al. Codon-optimized RPGR improves stability and efficacy of AAV8 gene therapy in two mouse models of X-linked retinitis pigmentosa. Mol Ther. 2017;25(8):1854–65.PubMedPubMedCentralCrossRefGoogle Scholar
- 52.Clinical Trials. Clinical evaluation of patients with X-linked retinitis pigmentosa (XLRP). Available from: https://clinicaltrials.gov/ct2/show/NCT03314207. Accessed 24 September 2018.
- 53.Clinical Trials. Natural history study of patients with X-linked retinal dystrophy associated with mutations in retinitis pigmentosa GTPase regulator (RPGR). Available from: https://clinicaltrials.gov/ct2/show/NCT03349242. Accessed 24 September 2018.
- 56.US National Library of Medicine. Choroideremia. Available from: https://ghr.nlm.nih.gov/condition/choroideremia. Accessed 9 March 2018.
- 77.Askou AL, Benckendorff JNE, Holmgaard A, Storm T, Aagaard L, Bek T, et al. Suppression of choroidal neovascularization in mice by subretinal delivery of multigenic lentiviral vectors encoding anti-angiogenic microRNAs. Hum Gene Ther Methods. 2017. https://doi.org/10.1089/hum.2017.079 [Epub ahead of print].
- 86.Gregori NZ, Lam BL, Davis JL. Intraoperative use of microscope-integrated optical coherence tomography for subretinal gene therapy delivery. Retina. 2017:1. https://doi.org/10.1097/IAE.0000000000001646. [Epub ahead of print].
- 89.Clinical Trials. REP1 gene replacement therapy for choroideremia (REGENERATE). Available from: https://clinicaltrials.gov/ct2/show/NCT02407678?cond=Choroideremia&rank=9. Accessed 17 May 2018.
- 91.Clinical Trials. A safety study of retinal gene therapy for choroideremia (GEMINI). Available from: https://clinicaltrials.gov/ct2/show/NCT03507686?cond=Choroideremia&rank=3. Accessed 17 May 2018.
- 93.Clinical Trials. Efficacy and safety of AAV2-REP1 for the treatment of choroideremia (STAR). Available from: https://clinicaltrials.gov/ct2/show/NCT03496012?cond=Choroideremia&rank=4. Accessed 16 May 2018.